Private Trust Co. NA Has $340,000 Holdings in Edwards Lifesciences Corporation $EW

Private Trust Co. NA increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 9.6% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,346 shares of the medical research company’s stock after purchasing an additional 380 shares during the quarter. Private Trust Co. NA’s holdings in Edwards Lifesciences were worth $340,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Allspring Global Investments Holdings LLC raised its holdings in shares of Edwards Lifesciences by 0.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after purchasing an additional 145 shares during the period. Pacific Capital Partners Ltd bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at about $1,760,000. Czech National Bank raised its holdings in shares of Edwards Lifesciences by 5.8% in the 2nd quarter. Czech National Bank now owns 143,385 shares of the medical research company’s stock valued at $11,214,000 after purchasing an additional 7,917 shares during the period. Mirova US LLC raised its holdings in shares of Edwards Lifesciences by 56.2% in the 2nd quarter. Mirova US LLC now owns 2,931,297 shares of the medical research company’s stock valued at $229,257,000 after purchasing an additional 1,054,301 shares during the period. Finally, Wealth Enhancement Advisory Services LLC raised its holdings in shares of Edwards Lifesciences by 13.5% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 77,016 shares of the medical research company’s stock valued at $5,582,000 after purchasing an additional 9,188 shares during the period. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Stock Up 0.9%

Shares of EW opened at $75.31 on Tuesday. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $83.00. The firm’s 50 day moving average is $77.48 and its 200-day moving average is $76.25. The stock has a market capitalization of $44.22 billion, a PE ratio of 10.84, a P/E/G ratio of 3.58 and a beta of 1.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the firm earned $0.70 earnings per share. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on EW. Royal Bank Of Canada increased their price target on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, July 25th. Evercore ISI set a $88.00 price target on shares of Edwards Lifesciences and gave the company an “outperform” rating in a report on Tuesday, October 7th. Truist Financial increased their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a report on Friday, July 25th. Morgan Stanley increased their price target on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. Finally, Piper Sandler increased their price target on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.06.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider directly owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This trade represents a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by company insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.